Genzyme

FDA & EMA plant approvals to cut bottlenecks at Genzyme

24-Jan-2012 By Nick Taylor

The FDA has followed the EMA in approving the Framingham, MA plant that Genzyme hopes will cut production bottlenecks.

UPDATE

Sanofi still suffering fall-out from Genzyme supply chain disruption

28-Sep-2011 By Natalie Morrison

The fall-out from Genzyme’s supply disruptions is still hindering Sanofi, more than five months after taking over the business.

EMA OK for second Shire Replagal plant

05-Jul-2011 By Gareth Macdonald

Shire has received European Medicines Agency (EMA) approval for a new US plant, doubling purification capacity for its Fabry disease drug Replagal.

Bilfinger Berger wins €30m deal for work on Genzyme plant

01-Jun-2011 By Nick Taylor

Bilfinger Berger has won a €30m ($43m) contract to help Genzyme add 8,000L of production capacity at its site in Geel, Belgium.

Genzyme manufacturing issue causes Thyrogen shortage

21-Mar-2011

Genzyme will be unable to meet demand for Thyrogen until July 2011 because of a manufacturing issue.

updated

CEO: Sanofi may provide Genzyme with fill/finish long term

17-Feb-2011 By Gareth Macdonald

Sanofi Aventis’ CEO, Chris Veibacher, said the French drugmaker may look at providing some fill/finish capacity for Genzyme in the long term.

Genzyme lowers guidance after Fabrazyme production delay

13-Jan-2011 By Nick Taylor

Genzyme has lowered 2011 financial projections after delaying the date it expects Fabrazyme production to return to normal.

Genzyme sells genetics lab; amid talk of staff cuts

13-Sep-2010 By Gareth Macdonald

Genzyme has confirmed plans to sell genetic testing unit to LabCorp for $925m amid media rumours that 1,000 employees face redundancy.

Sanofi goes public on $18.5bn bid for “unwilling” Genzyme

30-Aug-2010

Sanofi Aventis has gone public with its $18.5bn (€14.5bn) takeover bid for US biotech Genzyme, putting more pressure on firm’s “unwilling” board

US patients call for Fabrazyme patent break; Are you watching Sanofi?

03-Aug-2010 By Gareth Macdonald

Calls for US government to break Genzyme’s Fabrazyme patents accompany more speculation that French drugmaker Sanofi Aventis is in takeover talks.

EU majors reported to be looking at Genzyme

26-Jul-2010 By Gareth Macdonald

European drugmakers Sanofi-Aventis and GlaxoSmithKline (GSK) are rumoured to be looking at a possible acquisition of US biotechnology group Genzyme.

Genzyme inks expanded fill & finish deal with Hospira

08-Jul-2010 By Nick Taylor

Genzyme has entered into an expanded fill and finish manufacturing deal with Hospira as it works to move operations out of its Allston Landing plant.

Changes at Relypsa, Genzyme, Benitec, Genmab, Celsion, Alligator Bioscience – People on the move

23-Jun-2010 By Nick Taylor

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including changes at Relypsa, Genzyme, Benitec, Genmab, Celsion, Alligator Bioscience.

Manufacturing changes extend Genzyme’s Fabrazyme shortage

25-Feb-2010

Changes to manufacturing practices at Genzyme’s plant have led to further shortages of Fabrazyme (agalsidase beta), with production expected to remain below 30 per cent of demand until after June 30.

Genzyme’s preliminary revenues dip

13-Jan-2010 By Nick Taylor

Genzyme has reported a small dip in preliminary fourth quarter and full year revenues, driven by declining sales of Cerezyme and Fabrazyme which have been affected by manufacturing problems.